{"description":"An expected mild skin rash","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":2,"description":"Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"EG000","otherNumAffected":1,"otherNumAtRisk":2,"seriousNumAffected":0,"seriousNumAtRisk":2,"title":"Treatment (Enzyme Inhibitor Therapy)"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"An expected mild skin rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"NCI v4.01","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2,"numEvents":2}],"term":"Rash maculo-papular"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"NCI v4.01","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2,"numEvents":2}],"term":"Fatigue"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"NCI v4.01","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2,"numEvents":2}],"term":"Constipation"}],"timeFrame":"1 year"}